Addition of a Glucagon-like Peptide-1 to a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and Cardiovascular Disease.

Trial Profile

Addition of a Glucagon-like Peptide-1 to a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and Cardiovascular Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Ischaemic heart disorders; Obesity; Prediabetic-state; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jul 2013 Primary endpoint 'Bodyweight-reduction' has been met.
    • 22 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
    • 12 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top